What we do
What We Do
Cure Leukaemia was established in 2003 by Professor Charlie Craddock CBE and patients Graham Silk and Michael Woolley to allow patients with blood cancer in the Birmingham region to access remarkably effective new treatments which were then becoming available.
Since then, Cure Leukaemia has been able to expand to a national level, and we are now able to offer potential life-saving treatment to patients across the UK.
The Trials Acceleration Programme (TAP)
In January 2020, Cure Leukaemia began a 3-year, £3,000,000 commitment to funding the national Trials Acceleration Programme (TAP).
There are a total of 12 TAP centres across the UK, each with their own specialised Cure Leukaemia funded research nurse.
The TAP network allows patients to be connected with world-class and potentially lifesaving treatment that would otherwise not be available to them.
“We are now one of the leading centres in the world for the development of new drug and transplant treatments for patients with blood cancers. This is not only a great benefit to patients in the region but also to the reputation of Birmingham as a home of world-class medicine; in other words, this is world-class made in Birmingham.”
Professor Charlie Craddock CBE, Co-founder Cure Leukaemia
Why the Cure Leukaemia model works?
Over the past decade, Cure Leukaemia has funded a network of 15 specialist nurses who work across the West Midlands region to administer pioneering drug treatments to leukaemia patients.
The combination of the unique demographic of the West Midlands and the network of well-supported nurses have enabled us to leverage millions of pounds worth of pioneering drugs and give patients access to clinical trials for drugs not yet readily available on the NHS.
